Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Gets $1.2M From NCI to Build Protein Immunoassay Platform

NEW YORK, March 12 - Illumina will be getting $1.2 million from the National Cancer Institute to develop a multiplexed immunoassay system for proteins and post-translational protein modifications, the company said.

 

Illumina will design the system for use in identifying and exploring defects in the homeostasis of the lymphoid system, and the immune response to cancer.

 

The grant is a Phase 2 research grants funded through NCI's Innovative Molecular Analysis Technologies program. It will help the company adapt its microbead array technology, now used for DNA and RNA analysis, in order to measure and characterize proteins.

 

The company will partner with Christopher Goodnow, who is professor of molecular medicine at the Australian National University's John Curtin School for Medical Research. Goodnow's research centers on investigating lymphocyte reactions in order to understand autoimmune disorders, allergies, metastatic cancers, and diseases like leukemia and lymphoma.

He has previously worked with Illumina on a project to use arrays in order to investigate gene expression and protein activity in mutant mice.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.